Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Newton

Showing results (951-960 of 1,058) with videos related to

Pageof 106
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2007
Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humansMingxin Qian, Stephen A Bai, Bernice Brogdon, et al.
BMJ Open|July 16, 2020
Study protocol of the Health4Life initiative: a cluster randomised controlled trial of an eHealth school-based program targeting multiple lifestyle risk behaviours among young AustraliansMaree Teesson, Katrina E Champion, Nicola C Newton, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2003
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimizationChu-Biao Xue, Xiaohua He, John Roderick, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 15, 2006
Selective inhibition of eosinophil influx into the lung by small molecule CC chemokine receptor 3 antagonists in mouse models of allergic inflammationAnuk M Das, Krishna G Vaddi, Kimberly A Solomon, et al.
Journal of the National Cancer Institute|May 20, 2025
Leisure-time physical activity after diagnosis and survival by cancer type: a pooled analysisErika Rees-Punia, Lauren R Teras, Christina C Newton, et al.
The Lancet. Digital Health|April 26, 2024
Effectiveness of a universal, school-based, online programme for the prevention of anxiety, depression, and substance misuse among adolescents in Australia: 72-month outcomes from a cluster-randomised controlled trialMaree Teesson, Louise Birrell, Tim Slade, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 2007
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitorsXiao-Tao Chen, Bahman Ghavimi, Ronald L Corbett, et al.
ACS Chemical Biology|June 8, 2022
Sialic Acid Derivatives Inhibit SiaT Transporters and Delay Bacterial GrowthTiago Bozzola, Mariafrancesca Scalise, Christer U Larsson, et al.
Science Signaling|September 27, 2022
Mutations in protein kinase Cγ promote spinocerebellar ataxia type 14 by impairing kinase autoinhibitionCaila A Pilo, Timothy R Baffi, Alexandr P Kornev, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Potent and selective aggrecanase inhibitors containing cyclic P1 substituentsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.
Pageof 106

Showing results (951-960 of 1,058) with videos related to

Sort By:
Pageof 106
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2007
Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humansMingxin Qian, Stephen A Bai, Bernice Brogdon, et al.
BMJ Open|July 16, 2020
Study protocol of the Health4Life initiative: a cluster randomised controlled trial of an eHealth school-based program targeting multiple lifestyle risk behaviours among young AustraliansMaree Teesson, Katrina E Champion, Nicola C Newton, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2003
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimizationChu-Biao Xue, Xiaohua He, John Roderick, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 15, 2006
Selective inhibition of eosinophil influx into the lung by small molecule CC chemokine receptor 3 antagonists in mouse models of allergic inflammationAnuk M Das, Krishna G Vaddi, Kimberly A Solomon, et al.
Journal of the National Cancer Institute|May 20, 2025
Leisure-time physical activity after diagnosis and survival by cancer type: a pooled analysisErika Rees-Punia, Lauren R Teras, Christina C Newton, et al.
The Lancet. Digital Health|April 26, 2024
Effectiveness of a universal, school-based, online programme for the prevention of anxiety, depression, and substance misuse among adolescents in Australia: 72-month outcomes from a cluster-randomised controlled trialMaree Teesson, Louise Birrell, Tim Slade, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 2007
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitorsXiao-Tao Chen, Bahman Ghavimi, Ronald L Corbett, et al.
ACS Chemical Biology|June 8, 2022
Sialic Acid Derivatives Inhibit SiaT Transporters and Delay Bacterial GrowthTiago Bozzola, Mariafrancesca Scalise, Christer U Larsson, et al.
Science Signaling|September 27, 2022
Mutations in protein kinase Cγ promote spinocerebellar ataxia type 14 by impairing kinase autoinhibitionCaila A Pilo, Timothy R Baffi, Alexandr P Kornev, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Potent and selective aggrecanase inhibitors containing cyclic P1 substituentsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.
Pageof 106